Fig. 2From: TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth modelAR responsive gene expression in TMPRSS2-ERG fusion positive cells and enzalutamide regulation of AR responsive genes. QPCR analysis of AR responsive genes in VCaP scr shRNA and VCaP ERG shRNA cells (a) and changes in AR responsive genes upon enzalutamide treatment (b). * Represents p < 0.001 using student t-test and n = 3Back to article page